Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot Sells 6,820 Shares

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 6,820 shares of the company’s stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $44.86, for a total transaction of $305,945.20. Following the sale, the director now directly owns 344,683 shares of the company’s stock, valued at approximately $15,462,479.38. This represents a 1.94 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Pro-Dex Stock Performance

NASDAQ:PDEX opened at $44.35 on Friday. The company’s 50-day moving average is $48.26 and its two-hundred day moving average is $32.85. Pro-Dex, Inc. has a 1-year low of $16.18 and a 1-year high of $59.60. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.41 and a quick ratio of 1.94. The firm has a market capitalization of $144.58 million, a price-to-earnings ratio of 28.80 and a beta of 0.56.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in PDEX. FMR LLC raised its position in Pro-Dex by 34.9% in the third quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock valued at $119,000 after purchasing an additional 1,028 shares during the period. Renaissance Technologies LLC increased its position in shares of Pro-Dex by 7.9% during the 2nd quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier’s stock worth $240,000 after purchasing an additional 900 shares during the last quarter. Bard Associates Inc. raised its holdings in Pro-Dex by 17.6% in the 3rd quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier’s stock valued at $406,000 after buying an additional 2,031 shares during the period. Ritholtz Wealth Management acquired a new position in Pro-Dex in the fourth quarter valued at about $572,000. Finally, JPMorgan Chase & Co. boosted its stake in Pro-Dex by 2.2% during the third quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock worth $740,000 after buying an additional 529 shares during the period. 15.28% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. Ascendiant Capital Markets upped their price target on Pro-Dex from $30.00 to $52.00 and gave the company a “buy” rating in a research report on Monday, November 11th. StockNews.com upgraded Pro-Dex from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 14th.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.